Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30+
SponsorNorthwestern University
About this trial
The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treatments for heart failure.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
HFpEF criteria
Age ≥30 years.
Left ventricular ejection fraction ≥50% measured by echocardiography, CMR or MUGA (measured within one year + clinical stability)
Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center.
Disqualifiers
1. Inadequate echo or fluoroscopic images.
Trial population
Adults over 30 years of age.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
180 Participants
are grouped into 2 trial groupsGroup A: HFpEF
Group B: Non-HFpEF
Trial outcomes
Primary outcomes
1
Number of participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
Time frame
Up to 5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Northwestern University
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Massachusetts General Hospital
Collaborator
Brigham and Women's Hospital
Collaborator
Mayo Clinic
Collaborator
Wake Forest University Health Sciences
Collaborator
University of Pennsylvania
Collaborator
Source ClinicalTrials.gov